Our study uncovered a novel KEAP1-independent mechanism for NRF2 activation, suggesting the theoretical feasibility of developing a drug targeting NSUN2 to reduce the overall m5C level and malignant phenotype of cancer cells. This evidence concerns the gene NFE2L2 and cancer.